Emerald Mutual Fund Advisers Trust Has $2.30 Million Holdings in United Therapeutics Corporation $UTHR

Emerald Mutual Fund Advisers Trust increased its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 112.2% during the third quarter, Holdings Channel.com reports. The fund owned 5,474 shares of the biotechnology company’s stock after purchasing an additional 2,894 shares during the quarter. Emerald Mutual Fund Advisers Trust’s holdings in United Therapeutics were worth $2,295,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of UTHR. AQR Capital Management LLC grew its position in shares of United Therapeutics by 40.1% during the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock worth $362,876,000 after purchasing an additional 364,713 shares in the last quarter. Invesco Ltd. raised its position in shares of United Therapeutics by 90.2% in the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after buying an additional 419,588 shares in the last quarter. Assetmark Inc. raised its position in shares of United Therapeutics by 38.1% in the second quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock valued at $205,695,000 after buying an additional 197,384 shares in the last quarter. Norges Bank bought a new stake in shares of United Therapeutics in the second quarter valued at approximately $136,453,000. Finally, Amundi grew its position in United Therapeutics by 3.6% during the second quarter. Amundi now owns 362,826 shares of the biotechnology company’s stock worth $107,113,000 after buying an additional 12,633 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Down 0.7%

NASDAQ:UTHR opened at $468.94 on Friday. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $519.99. The stock’s 50-day simple moving average is $487.66 and its 200 day simple moving average is $414.12. The firm has a market capitalization of $20.19 billion, a PE ratio of 17.77, a price-to-earnings-growth ratio of 2.53 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping the consensus estimate of $6.89 by $0.27. The firm had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The business’s quarterly revenue was up 6.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $6.39 earnings per share. On average, analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $429.25, for a total value of $9,658,125.00. The sale was disclosed in a document filed with the SEC, which is available at this link. In the last ninety days, insiders have sold 563,364 shares of company stock worth $266,247,272. 10.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have weighed in on UTHR. HC Wainwright lifted their price objective on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Jefferies Financial Group restated a “buy” rating and issued a $575.00 price target on shares of United Therapeutics in a research report on Wednesday, November 19th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Morgan Stanley set a $447.00 price objective on shares of United Therapeutics in a research note on Wednesday, October 29th. Finally, Royal Bank Of Canada boosted their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $509.50.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.